American Medical Systems Inc.

San Jose, CA, United States

American Medical Systems Inc.

San Jose, CA, United States

Time filter

Source Type

News Article | May 15, 2017
Site: marketersmedia.com

— Rapid rise in the occurrence of chronic diseases has been one of the major drivers fueling the growth of Tissue ablation market. Moreover, increasing training programs by several device manufacturers for healthcare professionals on the usage of tissue ablation devices is propelling the market growth. However, reuse and reprocessing of devices in developing countries and stringent regulatory policies are hampering the growth of the global market. In terms of geography, North America dominates the market during the forecast period. Growth is attributed to increasing aged population and rise in a number of chronic diseases. Existence of a large number of regional and international vendors across the world makes Tissue ablation market highly competitive. Some of the key players in the market include Boston Scientific, Johnson & Johnson, Medtronic, St. Jude Medical , Abbott Laboratories, Acoustic Medsystems , Alcon, American Medical Systems, AtriCure, Philips Healthcare, Advanced Cardiac Therapeutics, Olympus, Vimecon and PLC Medical Systems. Regions Covered: • North America o US o Canada o Mexico • Europe o Germany o France o Italy o UK o Spain o Rest of Europe • Asia Pacific o Japan o China o India o Australia o New Zealand o Rest of Asia Pacific • Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 6 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements About Stratistics MRC We offer wide spectrum of research and consulting services with in-depth knowledge of different industries. We are known for customized research services, consulting services and Full Time Equivalent (FTE) services in the research world. We explore the market trends and draw our insights with valid assessments and analytical views. We use advanced techniques and tools among the quantitative and qualitative methodologies to identify the market trends. Our research reports and publications are routed to help our clients to design their business models and enhance their business growth in the competitive market scenario. We have a strong team with hand-picked consultants including project managers, implementers, industry experts, researchers, research evaluators and analysts with years of experience in delivering the complex projects. For more information, please visit http://www.strategymrc.com/


LONDON, UK / ACCESSWIRE / May 17, 2017 / Active Wall St. blog coverage looks at the headline from Boston Scientific Corp. (NYSE: BSX) as the Company announced on May 16, 2017, that it has closed the acquisition of Symetis SA, a privately-held Swiss structural heart Company, specializing in the development of minimally-invasive transcatheter aortic valve implantation (TAVI) devices. This announcement was made following the acquisition agreement on March 30, 2017, to acquire Symetis for about $435 million in cash. Register with us now for your free membership and blog access at: One of Boston Scientific's competitors within the Medical Appliances & Equipment space, Hologic, Inc. (NASDAQ: HOLX), reported on May 10, 2017, its financial results for the fiscal second quarter ended April 01, 2017. AWS will be initiating a research report on Hologic in the coming days. Today, AWS is promoting its blog coverage on BSX; touching on HOLX. Get all of our free blog coverage and more by clicking on the link below: With the completion of the acquisition agreement, Boston Scientific will hold control of Symetis operations across Europe and other geographies outside the United States. The Company will immediately start selling ACURATE TA™ and ACURATE neo™/TF™ valve in the respective markets and Symetis will become a subsidiary of the Boston Scientific Interventional Cardiology Division. Boston Scientific has an impressive portfolio of structural heart products, where the Symetis acquisition generates additional benefits through the complementary TAVI platforms which enable implanting physicians and hospitals to treat the widest range of patients and aortic valve anatomies. The Company views this agreement as a step to achieve continued growth while utilizing Symetis' portfolio, including valve offering and left atrial appendage closure device. The Company additionally announced positive results from the REPRISE III clinical trial, presented at the annual EuroPCR Scientific Program, in Paris, on May 16, 2017. Accordingly, data from the study demonstrated that the LOTUS Valve System, a TAVI system, showed superiority over the CoreValve TAVI System platform. Boston Scientific is primarily known for the development of Taxus Stent, a drug-eluting stent, used to open clogged arteries. The Company's cornerstone LOTUS Valve System platform finds the ACURATE valve portfolio accretive to it which is designed to treat patients suffering from severe symptomatic and aortic valve stenosis, considered high-risk segments for surgical valve replacement. The ACURATE platform is known for its ease of use during valve implantation where the replacement valve is delivered via a transcatheter percutaneous delivery system. This agreement to acquire Symetis follows the recent acquisition of Neovasc, Inc., manufacturing assets, and represents the Company's continued investment in the structural heart through intellectual property, research and development, and manufacturing capabilities. Boston Scientific plans to establish itself as the leader in TAVI and structural heart technologies under a long-term strategy. The Company is expanding its portfolio and product pipeline to address the needs of the global healthcare providers and their patients. Symetis, based in Ecublens, Switzerland, operates with about 300 employees worldwide. Symetis views this transaction as a step to further drive innovation and bank on Boston Scientific's legacy and strong leadership in interventional cardiology. The Company acquired EndoChoice Holdings, Inc., on September 27, 2016, in an attempt to diversify its portfolio in the endoscopy segment. The Company additionally acquired American Medical Systems, a provider of devices to treat enlarged oriostrate, urinary incontinence, and erectile dysfunction, on August 04, 2016, for about $1.6 billion, plus potential $50 million milestone payments. Boston Scientific recently reported its Q1 FY17 results on April 27, 2017, where it reported net sales of $2.16 billion for the quarter ending on March 31, 2017. Additionally, the cardiovascular segment of the Company reported a growth of 8% from $790 million for Q1 FY16 to $851 million for Q1 FY17. Boston Scientific's share price finished yesterday's trading session at $26.48, slightly up 0.23%. A total volume of 10.52 million shares exchanged hands, which was higher than the 3 months average volume of 7.42 million shares. The stock has surged 5.16% and 23.16% in the last three months and past six months, respectively. Furthermore, since the start of the year, shares of the Company have surged 22.42%. The stock is trading at a PE ratio of 84.60 and currently has a market cap of $36.46 billion. Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. AWS has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. LONDON, UK / ACCESSWIRE / May 17, 2017 / Active Wall St. blog coverage looks at the headline from Boston Scientific Corp. (NYSE: BSX) as the Company announced on May 16, 2017, that it has closed the acquisition of Symetis SA, a privately-held Swiss structural heart Company, specializing in the development of minimally-invasive transcatheter aortic valve implantation (TAVI) devices. This announcement was made following the acquisition agreement on March 30, 2017, to acquire Symetis for about $435 million in cash. Register with us now for your free membership and blog access at: One of Boston Scientific's competitors within the Medical Appliances & Equipment space, Hologic, Inc. (NASDAQ: HOLX), reported on May 10, 2017, its financial results for the fiscal second quarter ended April 01, 2017. AWS will be initiating a research report on Hologic in the coming days. Today, AWS is promoting its blog coverage on BSX; touching on HOLX. Get all of our free blog coverage and more by clicking on the link below: With the completion of the acquisition agreement, Boston Scientific will hold control of Symetis operations across Europe and other geographies outside the United States. The Company will immediately start selling ACURATE TA™ and ACURATE neo™/TF™ valve in the respective markets and Symetis will become a subsidiary of the Boston Scientific Interventional Cardiology Division. Boston Scientific has an impressive portfolio of structural heart products, where the Symetis acquisition generates additional benefits through the complementary TAVI platforms which enable implanting physicians and hospitals to treat the widest range of patients and aortic valve anatomies. The Company views this agreement as a step to achieve continued growth while utilizing Symetis' portfolio, including valve offering and left atrial appendage closure device. The Company additionally announced positive results from the REPRISE III clinical trial, presented at the annual EuroPCR Scientific Program, in Paris, on May 16, 2017. Accordingly, data from the study demonstrated that the LOTUS Valve System, a TAVI system, showed superiority over the CoreValve TAVI System platform. Boston Scientific is primarily known for the development of Taxus Stent, a drug-eluting stent, used to open clogged arteries. The Company's cornerstone LOTUS Valve System platform finds the ACURATE valve portfolio accretive to it which is designed to treat patients suffering from severe symptomatic and aortic valve stenosis, considered high-risk segments for surgical valve replacement. The ACURATE platform is known for its ease of use during valve implantation where the replacement valve is delivered via a transcatheter percutaneous delivery system. This agreement to acquire Symetis follows the recent acquisition of Neovasc, Inc., manufacturing assets, and represents the Company's continued investment in the structural heart through intellectual property, research and development, and manufacturing capabilities. Boston Scientific plans to establish itself as the leader in TAVI and structural heart technologies under a long-term strategy. The Company is expanding its portfolio and product pipeline to address the needs of the global healthcare providers and their patients. Symetis, based in Ecublens, Switzerland, operates with about 300 employees worldwide. Symetis views this transaction as a step to further drive innovation and bank on Boston Scientific's legacy and strong leadership in interventional cardiology. The Company acquired EndoChoice Holdings, Inc., on September 27, 2016, in an attempt to diversify its portfolio in the endoscopy segment. The Company additionally acquired American Medical Systems, a provider of devices to treat enlarged oriostrate, urinary incontinence, and erectile dysfunction, on August 04, 2016, for about $1.6 billion, plus potential $50 million milestone payments. Boston Scientific recently reported its Q1 FY17 results on April 27, 2017, where it reported net sales of $2.16 billion for the quarter ending on March 31, 2017. Additionally, the cardiovascular segment of the Company reported a growth of 8% from $790 million for Q1 FY16 to $851 million for Q1 FY17. Boston Scientific's share price finished yesterday's trading session at $26.48, slightly up 0.23%. A total volume of 10.52 million shares exchanged hands, which was higher than the 3 months average volume of 7.42 million shares. The stock has surged 5.16% and 23.16% in the last three months and past six months, respectively. Furthermore, since the start of the year, shares of the Company have surged 22.42%. The stock is trading at a PE ratio of 84.60 and currently has a market cap of $36.46 billion. Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. AWS has not been compensated; directly or indirectly; for producing or publishing this document. The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst, for further information on analyst credentials, please email info@activewallst.com. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way. AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.activewallst.com/disclaimer/. For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.


News Article | May 18, 2017
Site: www.prnewswire.com

LONDON, May 18, 2017 /PRNewswire/ -- According to Stratistics MRC, the Global Tissue Ablation Market is expected to grow at a CAGR of 9.4% during the forecast period 2016-2022. Rapid rise in the occurrence of chronic diseases has been one of the major drivers fueling the growth of Tissue ablation market. Moreover, increasing training programs by several device manufacturers for healthcare professionals on the usage of tissue ablation devices is propelling the market growth. However, reuse and reprocessing of devices in developing countries and stringent regulatory policies are hampering the growth of the global market. Download the full report: https://www.reportbuyer.com/product/4823105/ In terms of geography, North America dominates the market during the forecast period. Growth is attributed to increasing aged population and rise in a number of chronic diseases. Existence of a large number of regional and international vendors across the world makes Tissue ablation market highly competitive. Some of the key players in the market include Boston Scientific, Johnson & Johnson, Medtronic, St. Jude Medical , Abbott Laboratories, Acoustic Medsystems , Alcon, American Medical Systems, AtriCure, Philips Healthcare, Advanced Cardiac Therapeutics, Olympus, Vimecon and PLC Medical Systems. Type of Tissue ablation Covered: - Urology - Opthalmology - Oncology - Gynecology - Cosmetology - Cardiology Applications Covered: - Ultrasound ablation - Radiofrequency ablation - Microwaves ablation - Laser-based ablation - Hydrothermal ablation - EBRT - Cryoablation Devices Regions Covered: - North America o US o Canada o Mexico - Europe o Germany o France o Italy o UK o Spain o Rest of Europe - Asia Pacific o Japan o China o India o Australia o New Zealand o Rest of Asia Pacific - Rest of the World o Middle East o Brazil o Argentina o South Africa o Egypt What our report offers: - Market share assessments for the regional and country level segments - Market share analysis of the top industry players - Strategic recommendations for the new entrants - Market forecasts for a minimum of 6 years of all the mentioned segments, sub segments and the regional markets - Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations) - Strategic recommendations in key business segments based on the market estimations - Competitive landscaping mapping the key common trends - Company profiling with detailed strategies, financials, and recent developments - Supply chain trends mapping the latest technological advancements Download the full report: https://www.reportbuyer.com/product/4823105/ About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers http://www.reportbuyer.com For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: query@reportbuyer.com Tel: +44 208 816 85 48 Website: www.reportbuyer.com To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/tissue-ablation---global-market-outlook-2016-2022-300460249.html


News Article | May 26, 2017
Site: globenewswire.com

SOUTH JORDAN, Utah, May 26, 2017 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ:MMSI), a leading manufacturer and marketer of proprietary disposable medical devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology and endoscopy, announced today that it has appointed Thomas Gunderson to serve as a director of the Company. Gunderson recently retired from a 24-year career at Piper Jaffray where he covered numerous companies as a Senior Research Analyst for Medical Technology.  Prior to joining Piper Jaffray, he worked for 12 years at American Medical Systems, a private medical device company acquired by Pfizer in 1983.  Gunderson has served on several non-profit boards and is currently serving as Chairman of the Board of Directors of the Minneapolis Heart Institute Foundation, as a member of the Board of TransMedics, Inc., and as a director of the Abbott Northwestern Hospital Foundation. Gunderson was appointed by Merit’s Board of Directors to fill a vacancy which resulted from the resignation of Richard Edelman, who served as a director of Merit since the company’s founding and recently as Lead Director.  Merit’s Board of Directors also appointed Nolan Karras to assume the role of Lead Director. “We are pleased to have Thom Gunderson join our Board,” said Fred P. Lampropoulos, Merit’s Chairman and Chief Executive Officer.  “We believe his broad experience in observing, analyzing and reporting on medtech companies will bring a seasoned perspective to the Board as we continually seek to represent the best interests of our shareholders.  We would like to publicly thank Dick Edelman for his many years of dedication and service to Merit’s Board.” ABOUT MERIT Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture and distribution of proprietary disposable medical devices used in interventional, diagnostic and therapeutic procedures, particularly in cardiology, radiology and endoscopy.  Merit serves client hospitals worldwide with a domestic and international sales force totaling approximately 290 individuals.  Merit employs approximately 4,500 people worldwide with facilities in South Jordan, Utah; Pearland, Texas; Richmond, Virginia; Malvern, Pennsylvania; Rockland, Massachusetts; San Jose, California; Maastricht and Venlo, The Netherlands; Paris, France; Galway, Ireland; Beijing, China; Tijuana, Mexico; Joinville, Brazil; Markham, Ontario, Canada; Melbourne, Australia; Tokyo, Japan; and Singapore. FORWARD-LOOKING STATEMENTS Statements contained in this release which are not purely historical, including, without limitation, statements regarding Merit's forecasted plans, revenues, net income, financial results or anticipated or completed acquisitions, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties such as those described in Merit's Annual Report on Form 10-K for the year ended December 31, 2016 and subsequent filings with the Securities and Exchange Commission.  Such risks and uncertainties include risks relating to Merit's potential inability to successfully manage growth through acquisitions, including the inability to commercialize technology acquired through completed, proposed or future transactions; product recalls and product liability claims; expenditures relating to research, development, testing and regulatory approval or clearance of Merit's products and risks that such products may not be developed successfully or approved for commercial use; governmental scrutiny and regulation of the medical device industry, including governmental inquiries, investigations and proceedings involving Merit; reforms to the 510(k) process administered by the U.S. Food and Drug Administration; restrictions on Merit's liquidity or business operations resulting from its current debt agreements; infringement of Merit's technology or the assertion that Merit's technology infringes the rights of other parties; the potential of fines, penalties or other adverse consequences if Merit's employees or agents violate the U.S. Foreign Corrupt Practices Act or other laws or regulations; laws and regulations targeting fraud and abuse in the healthcare industry; potential for significant adverse changes in governing regulations; changes in tax laws and regulations in the United States or other countries; increases in the prices of commodity components; negative changes in economic and industry conditions in the United States or other countries; termination or interruption of relationships with Merit's suppliers, or failure of such suppliers to perform; fluctuations in exchange rates;  concentration of a substantial portion of Merit's revenues among a few products and procedures; development of new products and technology that could render Merit's existing products obsolete; market acceptance of new products; volatility in the market price of Merit's common stock; modification or limitation of governmental or private insurance reimbursement policies; changes in healthcare policies or markets related to healthcare reform initiatives; failure to comply with applicable environmental laws; changes in key personnel; work stoppage or transportation risks; introduction of products in a timely fashion; price and product competition; availability of labor and materials; fluctuations in and obsolescence of inventory; and other factors referred to in Merit's Annual Report on Form 10-K for the year ended December 31, 2016 and other materials filed with the Securities and Exchange Commission. All subsequent forward-looking statements attributable to Merit or persons acting on its behalf are expressly qualified in their entirety by these cautionary statements. Actual results will likely differ, and may differ materially, from anticipated results. Financial estimates are subject to change and are not intended to be relied upon as predictions of future operating results, and Merit assumes no obligation to update or disclose revisions to those estimates.


Dublin, May 25, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Biophotonics - A Global Market Overview" report to their offering. The market for Biophotonics forecast to be US$36.8 billion in 2017 and projected to reach US$59.9 billion by 2022 at a CAGR of robust 10.2% between 2017 and 2022. Imaging estimated the largest consumer of biophotonics with market worth US$20.3 billion 2017 and projected to grow by a CAGR of 10.3% during the same analysis period. Analytics & Sensing applications anticipated to grow at a faster phase at a CAGR of 10.4% to reach US$19.4 billion by 2022. The study exclusively analyzes the Biophotonics applications/sub-types, technologies and application sectors are analyzed in terms of USD for 2014-2022 analysis period across the global markets comprising North America, Europe, Asia-Pacific, Latin America and Rest of World. Global market for Biophotonics applications analyzed in this study include Analytics & Sensing, Imaging, and Processing & Curing. These applications further categorized in to Analytics & Sensing - Biosensors, Molecular Spectroscopy, Other Analytics & Sensing Applications; Imaging - Inside Imaging (Endoscopy), Optical Microscopy, See-Through Imaging and Surface Imaging; and Processing & Curing - Light Therapy and Other Processing & Curing. The report also explores the global markets of Biophotonics by end-use sectors comprising Medical Diagnostics, Medical Therapeutics, Tests & Components and Non-Medical Applications while special focus on technologies including In Vitro and In Vivo. Advancements in optical technology, high incidences of chronic diseases and increasing demand for minimally invasive surgeries are also contributing to the growth in Biophotonics. Emerging economies have yet to fully exploit the opportunities offered by Biophotonics, which is slated to propel demand in regions such as Asia-Pacific and Latin America. Despite these developments, it is anticipated that a bulk of the market for Biophotonics would be accounted for by its use in the medical sector. The technology offers capability of addressing some of the essential healthcare needs of an aging global population, which will remain a key factor in bolstering demand. Other significant factors contributing to growth in the market for Biophotonics include ongoing research and development activities in various applications and government support for novel cost-effective medical technologies. Key Topics Covered: 1. Introduction 1.1 Product Outline 1.1.1 A Primer on Photonics 1.1.2 An Overview of Biophotonics 2. Applications and End-Use Sectors 2.1 Biophotonics Applications 2.1.1 Analytics & Sensing 2.1.2 Imaging 2.1.3 Processing & Curing 2.2 End-Use Sectors For Biophotonics 2.2.1 Medical Diagnostics 2.2.2 Medical Therapeutics 3. Key Market Trends 3.1 Concurrent Imaging of 24 Molecules Enabled by Innovative Microscopy Platform 3.2 Innovative "Smart Needle" Makes Brain Surgery Safer 3.3 Medically Monitoring Cameras Show Promise as Alternatives to Skin Sensors 3.4 Disease Detection Made Easier with Nanoscale Sensor 3.5 Detection of Next-Generation DNA Sequencing Reactions Enabled with Smartphone Microscope 3.6 Monitoring of Brain's Response to Pain Facilitated with Optical Tool 3.7 Retinal Camera Eliminates the Need for Dilating Pupils 3.8 Biophotonics Expands Traditional Realms of Radiology 3.9 Rapid and Accurate Detection of Bacterial Growth in Perishables Enabled with TDLAS 3.10 Novel Biophotonic Light Sensor for Detecting Legionella Bacteria 3.11 Nanostructure-Based Biophotonics Enables Wide-Ranging Detection 3.12 Innovative Optical Technology for Effective Monitoring of Blood Glucose Levels on the Cards 3.13 Identification of Unstable Plaques Made Possible with Biophotonics 3.14 Revolutionary Raman Imaging Technique Promises Improved Cancer Detection 4. Key Global Players - Becton, Dickinson and Company (United States) - Biolase, Inc. (United States) - Bio-Rad Laboratories, Inc. (United States) - Biotek Instruments, Inc. (United States) - Carl Zeiss AG (Germany) - Coherent Inc. (United States) - Hamamatsu Photonics K.K. (Japan) - Horiba, Ltd. (Japan) - II-VI Incorporated (United States) - Lumenis Ltd. (Israel) - Newport Corporation (United States) - Olympus Corporation (Japan) - Olympus Corporation of the Americas (United States) - Perkinelmer Inc. (United States) - Picoquant (Germany) - Thermo Fisher Scientific Inc. (United States) - FEI Company, Inc. (United States) - Toshiba Medical Systems Corporation (Japan) - Zecotek Photonics Inc. (Canada) 5. Key Business Trends - Horiba Scientific and Manta Instruments, Inc Enter into Distribution Agreement - PicoQuant Launches Two new Single Photon Sensitive Hybrid Photo Detector - Oxford Instruments Asylum Research Unveils new SurfRider HQ-Series AFM Probes - Beckman Receives FDA Clearance for its DxC 700 AU Chemistry Analyzer - Beckman Unveils CytoFLEX LX flow Cytometer - BioTek Expands in China - ZEISS Unveils ZEISS EXTARO 300 Visual System - ZEISS Introduces ZEISS Crossbeam 550 Image System - Hitachi Technologies Develops new Transmission Electron Microscope (TEM)*1 model, the HT7800 Series - Thermo Fisher Introduces new robust iN5 FTIR microscope - Andor Unveils new iXon Life Camera Platform for Fluorescence Microscopy - Oxford Instruments Asylum Research Releases New Cypher VRS Video-Rate Atomic Force Microscope - Becton Announces Early Access Program for BD Resolve Single-Cell Analysis Platform - 510(k) FDA clearance and Worldwide Launch for BIOLASE's Waterlase Express All-Tissue Laser System - Bruker Launches MALDI PharmaPulse 2.0 Screening Solution - FUJIFILM Europe Releases ELUXEO Endoscopy System - GE Healthcare and Boston Children's Hospital Join Forces to Develop Imaging Technology - Andor Launches Ultrafast Spectroscopy-enabled sCMOS Detectors - FDA Clearance and Worldwide Launch of new Epic Pro Diode Laser System from BIOLASE - Bio-Rad to Acquire RainDance Tech - PerkinElmer, Inc Unveils Vectra® Polaris Automated Quantitative Pathology Imaging System - Bitplane Launches Imaris 8.4 Filament Tracer - Leica Microsystems Enters into Agreement with Columbia University - Olympus Corporation Launches New Olympus DP74 Color Microscope Camera - Becton Unveils diagnostic instrument BD Phoenix M50 ID/AST - BIOLASE Inks a Clinical Research Agreement with McGuire Institute - Bruker to Acquire Preclinical PET Imaging Business of Oncovision - ENDRA Launches Nexus 128+ photoacoustic Imaging Solution - Shimadzu Corporation Releases SPM-9700HT Scanning Probe Microscope - Ocean Optics Releases New SERS Nanosponge Substrate for Raman Spectroscopy Applications - Andor Introduces Dragonfly, a new Imaging Solution - Bruker Releases In-Vivo Xtreme II Optical Preclinical Imaging System - Oxford Instruments Plc Introduces X-MET8000 series of X-ray fluorescence (XRF) analyzers - Bruker Releases Scanning Microwave Impedance Microscopy Solution - Bruker Unveils S4 TStar, a Total Reflection X-ray Fluorescence (TXRF) Spectrometer - ENDRA and GE Healthcare Collaborate - Thermo Fisher Acquires FEI Company - Olympus Medical Introduces EZ Shot 3 Plus single use Aspiration Needle for Endoscopic Application - BioTek and MilliporeSigma Collaborate - MedCom GmbH and Hitachi Medical Systems Europe Enter into Distribution Agreement - Becton Launches a novel cell analyzer BD FACSymphony system - Bio-Rad Announces CE IVD marking for its QX200 Droplet Digital PCR (ddPCR) System - Biophotonic Unveils new Pulse Shaping System, FemtoJockD - Boston Launches LithoVue Single-Use Digital Flexible Ureteroscope - Nikon Corporation Introduces new Inverted Routine Microscope ECLIPSE Ts2 - Andor Launches new Ultrasensitive Zyla 4.2 PLUS Scientific CMOS (sCMOS) Camera - Bruker Launches new SKYSCAN 1275 Automated, Desktop Micro-CT System - Boston Completes the Acquisition of American Medical Systems' (AMS) Men's Health and Prostate Health business - OpGen, Inc. Plans to Acquire AdvanDx, Inc. - OpGen, Inc Launches Next-Generation Molecular Testing and Bioinformatics for Combating Multi-Drug Resistant Infections - Bio-Rad Introduces BioPlex® 2200 25-OH Vitamin D kit - Leica Microsystems Unveils Inverted Microscope, Leica DMi8 - Boston Introduces Next Generation SpyGlass DS Direct Visualization System - Beckman to Acquire Clinical Microbiology Business from Siemens Healthcare Diagnostics - Boston Unveils new POLARIS Imaging System - Beckman Releases new Aquios CL Clinical Flow Cytometer 6. Global Market Overview For more information about this report visit http://www.researchandmarkets.com/research/3vgm3p/biophotonics_a

Loading American Medical Systems Inc. collaborators
Loading American Medical Systems Inc. collaborators